

# Appendix 4D

## Half-Year Consolidated Financial Report

Introduced 1/1/2003.

<b>Name of Entity</b>	OBJ LIMITED
<b>ABN</b>	72 056 482 636
<b>Financial Period Ended</b>	31 DECEMBER 2017
<b>Previous Corresponding Reporting Period</b>	31 DECEMBER 2016

### Results for Announcement to the Market

	\$'000	Percentage increase /(decrease) over previous corresponding period
<b>Revenue</b>	1,610	Up 12%
<b>Loss for the period</b>	(410)	Down (83%)
<b>Loss attributable to members of the parent entity</b>	(410)	Down (83%)
<b>Dividends (distributions)</b>	<b>Amount per security</b>	<b>Franked amount per security</b>
<b>Final Dividend</b>	Nil	Nil
<b>Interim Dividend</b>	Nil	Nil
<b>Previous corresponding period *</b>	Nil	Nil
<b>Record date for determining entitlements to the dividends (if any)</b>	N/A	
<b>Brief explanation of any of the figures reported above necessary to enable the figures to be understood:</b>		
Refer to the Review of Operations section of the Directors' Report included.		

**The half-year consolidated financial report is to be read in conjunction with the most recent annual financial report.**

## Dividends

Date the dividend is payable	N/A
Record date to determine entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign sourced dividend or distribution	N/A
Details of any dividend reinvestment plans in operation	N/A
The last date for receipt of an election notice for participation in any dividend reinvestment plans	N/A

## NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	\$0.003	\$0.004

## Other Significant Information Needed by an Investor to Make an Informed Assessment of the Entity's Financial Performance and Financial Position

Refer to the Review of Operations section of the Directors' Report included.

## **Commentary on the Results for the Period**

**The earnings per security and the nature of any dilution aspects :**

Refer to the Statement of Comprehensive Income included.

**Returns to shareholders including distributions and buy backs :**

N/A

**Significant features of operating performance :**

Refer to the Review of Operations section of the Directors' Report included.

**The results of segments that are significant to an understanding of the business as a whole:**

N/A

**Discussion of trends in performance :**

Refer to the Review of Operations section of the Directors' Report included.

**Any other factor which has affected the results in the period or which are likely to affect results in the future, including those where the effect could not be quantified:**

N/A

### Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	N/A
Date control gained	N/A
Consolidated profit / (loss) from ordinary activities since the date in the current period on which control was acquired	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period	N/A

### Loss of Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	N/A
Date control lost	N/A
Consolidated profit / (loss) from ordinary activities for the current period to the date of loss of control ('\$000)	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) while controlled for the whole of the previous corresponding period ('\$000)	N/A

### Details of Associates and Joint Venture Entities


Name of Entity	Percentage Held		Share of Net Profit	
	Current Period	Previous Period	Current Period	Previous Period
N/A				
<b>Aggregate Share of Net Profits</b>				

## Audit/Review Status

<b>This half-year consolidated financial report is based on accounts to which one of the following applies:</b> (Tick one)			
The accounts have been audited		The accounts have been subject to review	<b>X</b>
The accounts are in the process of being audited or subject to review		The accounts have not yet been audited or reviewed	
<b>If the accounts have not yet been audited or subject to review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification:</b>			
N/A			
<b>If the accounts have been audited or subject to review and are subject to dispute or qualification, a description of the dispute or qualification:</b>			
N/A			

### Attachments Forming Part of Appendix 4D

Attachment #	Details
1	Interim Consolidated Financial Report

<b>Signed By (Director)</b>	
<b>Print Name</b>	Jeffrey Edwards
<b>Date</b>	23 <sup>rd</sup> February 2018

**OBJ LIMITED**  
**A.B.N. 72 056 482 636**

**DIRECTOR'S REPORT**

The directors present their consolidated financial statements on the results of OBJ Limited and its controlled entities for the financial half-year ended 31 December 2017.

**Directors**

The names of directors in office at any time during or since the end of the period are:

Mr Jeffrey David Edwards	
Dr Christopher John Quirk	
Mr Steven Lorn Schapera	(appointed: 01/08/2017)
Mr Glyn Gregory Horne Denison	(resigned: 02/02/2018)

With the exception of Mr Schapera, each of the other directors have been in office since the start of the financial year to the date of this report.

**Operating Result**

The net consolidated loss of the Consolidated Entity after providing for income tax amounted to \$410,179 (31 December 2016: loss of \$2,452,847).

**Review of Operations**

**Overview**

Over the period, OBJ has consolidated the licensing program with Procter & Gamble (P&G) with two products now present in the Asian market. P&G has informed OBJ that more than one million products containing microarray have been produced. Re-orders are expected.

The license fees received in the September quarter principally came from the sale of the Magnetic power booster under the SK-II brand and the first sales for the new Magnemask under the Olay brand.

During the period, the parties drafted an agreement defining the key terms of P&G's license for the second technology. This agreement is ready for execution by both parties, upon which will see both of the core OBJ technologies licensed to P&G for skin care only. Pending Addendums to the microarray licensing agreement will narrow P&G's exclusivity to skin care only. This enables OBJ to invest directly into branded products containing its technologies. OBJ intends to work alongside experienced distributors to bring these products to market. The Bodyguard program is, overall, an example of such a direct investment by OBJ in end products that contain OBJ's technology but will be brought to market by third party distributors.

Work continued as planned for the development of the Bodyguard product that now embraces both natural formulations (OBJ's Lubricen) and other formulations directed at pain relief such as ibuprofen (IBU).

**Procter and Gamble**

*Microarray*

Over the period, OBJ's Licensee continued selling the magnetic power booster applicator through its SK-II brand, as well as commenced preparations for the launch of the Magnemask product through its Olay brand. The initial focus of both has been Asian markets.

OBJ LIMITED  
A.B.N. 72 056 482 636

**DIRECTOR'S REPORT (*continued*)**

**Review of Operations (*continued*)**

Key points of the OBJ's Licensee relationship and activities include:

- The 40 prototypes required to be developed under the existing licensing agreement for the second technology have been delivered for initial consumer efficacy testing. This fulfils the first important phase of the program and enables consumer feedback to define the next stage, including the development of final products and software;
- The detailed licensing agreement has been finalised and is awaiting execution. The Board has taken the view that with the recent changes to its composition, it should hold off on signing the agreement until the full implications are well understood by all directors and to this end Mr Schapera will involve himself directly in these negotiations;
- Discussions continue to take place with the Singapore-based Product Accelerator regarding the development and distribution of products containing the second technology. The possible roles for OBJ in this venture remain to be negotiated;
- An Addendum is being negotiated that confines the areas of OBJ's Licensee's exclusivity to OBJ's microarray technology to a narrower range of skin care applications. The sectors previously captured under the exclusivity included colour cosmetics, hair care and shaving. These will now be released back to OBJ, enabling OBJ to offer products to the market containing microarray technology in these sectors;
- This Addendum has been negotiated as part of the Company's strategy to develop its own products for direct or indirect commercialisation. OBJ desires to participate in the ownership of those brands utilising its technology. This will provide for increased potential revenue to the Company rather than a sole reliance on the receipt of license fees. OBJ has been heavily involved in the design and development of various products with its licensee and continues to do so. That experience is now being directed at OBJ's own products and a number of market sectors have already been identified for OBJ product development;
- OBJ will continue to support its key licensee for its technologies (two of which apply to skin care) in defined territories while pursuing the developments of its own products in parallel. OBJ is already working in one market sector that has been released by OBJ's Licensee; and
- The Olay Magnemask has now been launched into North America through a number of America's largest retail chains including Walgreens, Target and Amazon. The US launch builds upon the existing sales in certain Asian markets.

*Other Activities*

Over the period, meetings were held in Japan with OBJ's Licensee to discuss the next two product developments, expected to be launched over the next 12 to 24 months to augment the existing products now in circulation.



While in Japan, OBJ's Managing Director Jeffrey Edwards received OBJ's Licensee's Partner of the Year award, from Mr Stanislav Vecera, President of Proctor and Gamble in Japan. The award recognising the creation of value from OBJ's innovation, as displayed by the success of the initial products containing the microarray in Asian markets.

---

OBJ LIMITED  
A.B.N. 72 056 482 636

**DIRECTOR'S REPORT (*continued*)**

**Review of Operations (*continued*)**

**OBJ Internal Product Innovations**

**BodyGuard / BodyCare**

Further to internal discussion, OBJ's management has decided that the name BodyCare will now reference applications for therapeutic and pharmaceutical use (e.g. IBU), and BodyGuard will reference applications containing the naturally occurring Lubricen formulation.

In essence, BodyGuard seeks to guard against the users' loss of functionality, whilst BodyCare aims to assist in the treatment of muscular skeletal and inflammatory pain. The hardware remains largely the same while the formulation embedded within will vary for the different applications. This split in brand structure will assist the Company in optimising distribution and rollout.

BodyGuard and BodyCare have matured further over this period with:

- The Curtin University clinical trial for IBU delivery (BodyCare) continues following the approval of the ethics committee and is expected to be completed during the March quarter. A major US-based potential licensee of the technology is awaiting these results before deciding whether to take on the BodyCare application. The trial will demonstrate the first use of the BodyCare product for pain relief; and
- A UK clinical trial has also been agreed to trial the BodyGuard product across a number of participants. The BodyGuard prototypes are being prepared by OBJ's preferred manufacturing partner based in Melbourne with the trial expected to commence during the March quarter.

The above trials demonstrate the potential of the BodyGuard/BodyCare product range to deliver a wide range of active ingredients to service the raft of market sectors that exist for the overall program across multiple distribution channels.

In the coming period, meetings are expected to take place in Melbourne with OBJ's preferred manufacturing partner with regard to intended next steps. The preferred partner has first right of refusal to manufacture and a non-exclusive right to distribute BodyGuard products via the Collaboration Agreement executed in 2017.

**Surface Hygiene**

OBJ continues its work with a UK based multi-national which is a market leader in surface cleaning. The party is presently testing OBJ's microarray technology in its laboratory for potential use with its well-known hygiene brands. Testing is well progressed and the party is replicating previous testing that was undertaken with significant success in Perth. The two teams are expected to meet again during the March quarter to determine next steps.

OBJ continues to invest development time into this exciting opportunity for the Company outside biological markets, and it remains optimistic regarding its ability to secure a suitable distribution partner in the short term.

---

OBJ LIMITED  
A.B.N. 72 056 482 636

**DIRECTOR'S REPORT (*continued*)**

**Review of Operations (*continued*)**

**DCE**

Caps containing the DCE technology are under evaluation in Singapore with a new potential multi-national partner that OBJ has been fostering for some time. The opportunity here is for OBJ to supply packaging for end-user products containing the Company's DCE layering technology. The potential partner will undertake consumer evaluation work before progressing discussions with OBJ in the coming months.

**The Board of Directors**

The Board is committed to its restructure. This will entail increasing the number of directors with each director bringing desirable skills and experience to the table. Whilst the initial search focussed on Australia, this search has been expanded internationally to recognise the global potential for OBJ's innovation. The directors have interviewed a number of potential candidates to join the Board as part of this proposed restructuring. The directors are confident this will provide critical additional depth of skill sets as the Company executes on its product strategies. It is expected that one or possibly two suitably qualified candidates will be invited to join the Board in the March quarter.

---

OBJ LIMITED  
A.B.N. 72 056 482 636

**DIRECTOR'S REPORT (*continued*)**

**Principal Activities**


The principal activities of the Consolidated Entity during the financial half-year ended 31 December 2017 were research and development for its Dermaportation and ETP transdermal drug delivery technologies.

There were no significant changes in the nature of the Consolidated Entity's principal activities during the financial half-year other than those referred to in the Review of Operations.

**Auditor's Independence Declaration**

In accordance with the Audit Independence requirements of the Corporations Act 2001, the directors have received and are satisfied with the "Audit Independence Declaration" provided by OBJ Limited external auditors RSM Australia Partners. The Audit Independence Declaration is included within this consolidated financial report.

Signed in accordance with a resolution of the board of directors pursuant to section 306(3)(a) of the Corporations Act 2001.



---

Jeffrey Edwards  
Director

Dated this 23<sup>rd</sup> day of February 2018

**RSM Australia Partners**

Level 32, Exchange Tower  
2 The Esplanade WA 6000  
GPO Box R1253 Perth WA 6844

T +61(0) 8 9261 9100  
F +61(0) 8 9261 9111

[www.rsm.com.au](http://www.rsm.com.au)


**AUDITOR'S INDEPENDENCE DECLARATION**

As lead auditor for the review of the financial report of OBJ Limited for the half-year ended 31 December 2017, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.



RSM AUSTRALIA PARTNERS



TUTU PHONG  
Partner

Perth, WA  
Dated: 23 February 2018

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
FOR THE HALF-YEAR ENDED 31 DECEMBER 2017**

	<b>31 Dec. 2017 \$</b>	<b>31 Dec. 2016 \$</b>
Revenue	1,083,206	1,415,685
Royalties	526,727	24,258
Net foreign exchange losses	(10,910)	(164)
Borrowing costs	(7,003)	(7,004)
Depreciation expenses	(47,801)	(73,057)
Administration fees	(259,909)	(238,970)
Auditor's remuneration	(13,000)	(12,000)
Consultants and consultants benefits expenses	(95,103)	(788,713)
Directors and employees benefits expenses	(897,841)	(2,192,870)
Legal costs	(35,982)	(26,248)
Materials and requisites	(32,304)	(16,506)
Occupancy expenses	(92,778)	(70,099)
Patent fees	(104,448)	(39,200)
Product design and trial testing expenses	(120,228)	(116,076)
Travel and accommodation	(56,409)	(37,767)
Other expenses	(246,396)	(274,116)
<b>Loss before income tax</b>	<b>(410,179)</b>	<b>(2,452,847)</b>
Income tax expense	--	--
<b>Loss for the period</b>	<b>(410,179)</b>	<b>(2,452,847)</b>
Other comprehensive income	--	--
<b>Total comprehensive loss for the period</b>	<b>(410,179)</b>	<b>(2,452,847)</b>
<b>Loss attributable to:</b>		
Members of the parent entity	(410,179)	(2,452,847)
	<b>Cents</b>	<b>Cents</b>
Basic and diluted losses per share (cents per share)	(0.02)	(0.14)

*The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.*

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 31 DECEMBER 2017**

	Note	31 Dec. 2017 \$	30 Jun. 2017 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents		4,776,854	5,373,442
Trade and other receivables		750,597	398,737
<b>TOTAL CURRENT ASSETS</b>		<u>5,527,451</u>	<u>5,772,179</u>
<b>NON CURRENT ASSETS</b>			
Plant and equipment		419,438	433,911
<b>TOTAL NON CURRENT ASSETS</b>		<u>419,438</u>	<u>433,911</u>
<b>TOTAL ASSETS</b>		<u>5,946,889</u>	<u>6,206,090</u>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		212,321	230,911
Borrowings		231,000	224,000
Employee benefits provision		57,671	49,124
<b>TOTAL CURRENT LIABILITIES</b>		<u>500,992</u>	<u>504,035</u>
<b>TOTAL LIABILITIES</b>		<u>500,992</u>	<u>504,035</u>
<b>NET ASSETS</b>		<u>5,445,897</u>	<u>5,702,055</u>
<b>EQUITY</b>			
Issued capital	2	31,920,508	31,766,487
Reserves	3	4,739,610	4,739,610
Accumulated losses		(31,214,221)	(30,804,042)
<b>TOTAL EQUITY</b>		<u>5,445,897</u>	<u>5,702,055</u>

*The above consolidated statement of financial position  
should be read in conjunction with the accompanying notes.*

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE HALF-YEAR ENDED 31 DECEMBER 2017**

	<b>Issued Capital</b>	<b>Share Based Payments Reserve</b>	<b>Accumulated Losses</b>	<b>Total Equity</b>
	\$	\$	\$	\$
<b>Balance at 1 July 2016</b>	31,346,219	3,689,386	(27,759,834)	7,275,771
Total comprehensive loss for the period	--	--	(2,452,847)	(2,452,847)
Shares issued during the period	425,210	--	--	425,210
Performance rights issued during the period	--	1,504,224	--	1,504,224
Transaction costs	(4,942)	--	--	(4,942)
<b>Balance at 31 December 2016</b>	<b>31,766,487</b>	<b>5,193,610</b>	<b>(30,212,681)</b>	<b>6,747,416</b>
<b>Balance at 1 July 2017</b>	31,766,487	4,739,610	(30,804,042)	5,702,055
Total comprehensive loss for the period	--	--	(410,179)	(410,179)
Shares issued during the period	162,443	--	--	162,443
Transaction costs	(8,422)	--	--	(8,422)
<b>Balance at 31 December 2017</b>	<b>31,920,508</b>	<b>4,739,610</b>	<b>(31,214,221)</b>	<b>5,445,897</b>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.*

**CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE HALF-YEAR ENDED 31 DECEMBER 2017**

	<b>31 Dec. 2017</b>	<b>31 Dec. 2016</b>
	<b>\$</b>	<b>\$</b>
<b>Cash flows from operating activities</b>		
Receipts from customers	1,213,163	93,620
Payments to suppliers and employees	(1,980,551)	(1,793,492)
Interest received	62,429	100,453
Borrowing costs	(3)	(4)
	<hr/>	<hr/>
<b>Net cash used in operating activities</b>	<b>(704,962)</b>	<b>(1,599,423)</b>
	<hr/>	<hr/>
<b>Cash flows from investing activities</b>		
Payments for plant and equipment	(34,737)	(169,648)
	<hr/>	<hr/>
<b>Net cash used in investing activities</b>	<b>(34,737)</b>	<b>(169,648)</b>
	<hr/>	<hr/>
<b>Cash flows from financing activities</b>		
Proceeds from issue of shares and options	162,443	--
Transaction costs from issue of shares and options	(8,422)	(4,942)
	<hr/>	<hr/>
<b>Net cash provided by/(used in) financing activities</b>	<b>154,021</b>	<b>(4,942)</b>
	<hr/>	<hr/>
Net decrease in cash and cash equivalents held	(585,678)	(1,774,013)
Cash and cash equivalents at the beginning of the financial period	5,373,442	7,334,205
Effect of exchange rate changes on cash holdings	(10,910)	(164)
	<hr/>	<hr/>
<b>Cash and cash equivalents at the end of the financial period</b>	<b>4,776,854</b>	<b>5,560,028</b>
	<hr/> <hr/>	<hr/> <hr/>

*The above consolidated statement of cash flows  
should be read in conjunction with the accompanying notes.*

---

## NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

### NOTE 1: BASIS OF PREPARATION

The half-year consolidated financial report is a general purpose financial report prepared in accordance with the requirements of the *Corporations Act 2001* and Accounting Standard AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures that the financial report and notes also comply with International Financial Reporting Standard IAS 34: Interim Financial Reporting.

It is recommended that this consolidated financial report be read in conjunction with the annual financial report for the year ended 30 June 2017 and any public announcements made by OBJ Limited and its controlled entities during the half-year in accordance with the continuous disclosure requirements arising under the *Corporations Act 2001*.

The half-year consolidated financial report does not include full disclosures of the type normally included in annual financial reports.

Except for cash flow information, the half-year consolidated financial report has been prepared on an accruals basis and is based on historical costs.

The accounting policies have been consistently applied by the Consolidated Entity and are consistent with those in the 30 June 2017 annual financial report, unless otherwise stated.

#### **New and Revised Accounting Standards and Interpretations**

The Consolidated Entity has adopted all of the new and revised Accounting Standards and Interpretations issued by the Australian Accounting Standards Board that are mandatory for the current reporting period. The adoption of these new and revised Accounting Standards and Interpretations has not resulted in a significant or material change to the Consolidated Entity's accounting policies.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted by the Consolidated Entity.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (*continued*)

**NOTE 2: ISSUED CAPITAL**

	<b>Consolidated</b>	
	<b>31 Dec. 2017</b>	<b>30 Jun. 2017</b>
	<b>\$</b>	<b>\$</b>
<b>(a) Issued capital</b>		
1,805,462,635 Ordinary shares fully paid (30/06/17: 1,775,547,109)	31,920,508	31,766,487
	<u>31,920,508</u>	<u>31,766,487</u>
<b>(b) Movements in ordinary share capital</b>	<b>Number of Shares</b>	<b>\$</b>
01/07/2017 Opening balance	1,775,547,109	31,766,487
06/07/2017 Placement to nominated entity of Mr Steven Schapera	3,248,860	162,443
31/08/2017 Pursuant to satisfaction of Performance Milestone 1	15,000,000	--
31/08/2017 Pursuant to satisfaction of Performance Milestone 1	11,666,666	--
Less: costs associated with the issue of shares		<u>(8,422)</u>
31/12/2017 Closing balance	<u>1,805,462,635</u>	<u>31,920,508</u>

**NOTE 3: RESERVES**

	<b>Consolidated</b>	
	<b>31 Dec. 2017</b>	<b>30 Jun. 2017</b>
	<b>\$</b>	<b>\$</b>
<b>(a) Composition</b>		
Share based payments reserve	<u>4,739,610</u>	<u>4,739,610</u>

The share based payments reserve records items recognised as expenses on valuation of director/employee/consultant share options and performance rights.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (*continued*)

**NOTE 3: RESERVES (*continued*)**

**(b) Movements in options and performance rights were as follows:**

Date	Details	Number of Performance Rights	Number of Options Listed	Number of Options Unlisted	Exercise Price	Fair Value of Options/Perf. Rights Issued	Expiry Date
01/07/17	Opening Balance	82,000,000	--	7,500,000	--	\$4,739,610	--
31/08/17	Pursuant to satisfaction of Performance Milestone 1	(15,000,000)	--	--	--	--	--
31/08/17	Pursuant to satisfaction of Performance Milestone 1	(11,666,666)	--	--	--	--	--
28/11/17	Expired Performance Rights	(55,333,334)	--	--	--	--	--
31/12/17	Closing Balance	--	--	7,500,000	--	\$4,739,610	--

**NOTE 4: DIVIDENDS**

There have been no dividends declared or recommended and no distributions made to shareholders or other persons during the period.

**NOTE 5: SEGMENT INFORMATION**

The Consolidated Entity has considered the requirements of AASB8 – Operating Segments and has identified its operating segments based on the internal reports that are reviewed and used by the board of directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

The Consolidated Entity operates as a single segment which is development of the dermaportation drug delivery technology within Australia.

The Consolidated Entity is domiciled in Australia. All revenue from external parties is generated from Australia only. Segment revenues are allocated based on the country in which the party is located. Operating revenues of approximately \$682,554 or 42% (31/12/2016 – \$122,143 or 8%) are derived from a single external party.

All the assets are located in Australia only. Segment assets are allocated to countries based on where the assets are located.

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)****NOTE 6: CONTINGENT ASSETS AND LIABILITIES**

The directors of the Company are unaware of any existing contingent assets and liabilities, other than the contingent liability matter regarding the Company being served with a writ over a convertible note, as previously announced to the market. The Company has retained legal representation for the active defence of the matter, to which mediation continues.

**NOTE 7: EVENTS SUBSEQUENT TO REPORTING DATE**

Subsequent to the end of the half-year ended 31 December 2017, the following event had occurred:

- On 2 February 2018, Mr Glyn Denison formally retired as a director of the Company.

---


OBJ LIMITED  
A.B.N. 72 056 482 636

**DIRECTORS' DECLARATION**

In the opinion of the directors:

- a) The financial statements and notes are in accordance with the Corporations Act 2001, including:
  - i) giving a true and fair view of the Consolidated Entity's financial position as at 31 December 2017 and of its performance for the half-year ended on that date; and
  - ii) complying with Australian Accounting Standards AASB 134: Interim Financial Reporting, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the board of directors pursuant to section 303(5)(a) of the Corporations Act 2001.



\_\_\_\_\_  
Jeffrey Edwards  
Director

Dated this 23<sup>rd</sup> day of February 2018

**RSM Australia Partners**

Level 32, Exchange Tower  
2 The Esplanade WA 6000  
GPO Box R1253 Perth WA 6844

T +61 (0) 8 92619100  
F +61 (0) 8 92619111

[www.rsm.com.au](http://www.rsm.com.au)

**INDEPENDENT AUDITOR'S REVIEW REPORT  
TO THE MEMBERS OF  
OBJ LIMITED**

We have reviewed the accompanying half-year financial report of OBJ Limited, which comprises the statement of financial position as at 31 December 2017, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

*Directors' Responsibility for the Half-Year Financial Report*

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

*Auditor's Responsibility*

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of OBJ Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

*Independence*

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of OBJ Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.


*Conclusion*

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of OBJ Limited is not in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2017 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

RSM

RSM AUSTRALIA PARTNERS



TUTU PHONG  
Partner

Perth, WA  
Dated: 23 February 2018